Surface Oncology (NASDAQ: SURF)
Surface Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Surface Oncology Company Info
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
News & Analysis
Why AstraZeneca and Surface Oncology Rose Today
The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.
This Is Why Surface Oncology Is a Great Stock to Buy Right Now
It's the right time to be decisive, if you can tolerate uncertainty.
Could Surface Oncology Be a Millionaire-Maker Stock?
Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.
Why Surface Oncology Stock Is Soaring Today
The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.
Why Surface Oncology Is Flying Higher After Hours Today
Its pancreatic cancer drug gets a nod from the FDA.
Why Surface Oncology Stock Sank Today
Investors reacted negatively to a big licensing deal.
Why Surface Oncology Stock Soared Today
The small biotech could be preparing to sell to a big drugmaker.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.